دورية أكاديمية

A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score.

التفاصيل البيبلوغرافية
العنوان: A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score.
المؤلفون: Zheng, Xinlong, Lu, Tao, Wu, Shiwen, Lin, Xiaoyan, Bai, Jing, Chen, Xiaohui, Miao, Qian, Yan, Jianqun, Jiang, Kan, Zhang, Longfeng, Zheng, Xiaobing, Wang, Haibo, Xu, Yiquan, Xiao, Weijin, Li, Cao, Peng, Wenying, Ding, Jianming, Zhong, Qiaofeng, Zou, Zihua, Yang, Shanshan
المصدر: MedComm; Mar2024, Vol. 5 Issue 3, p1-14, 14p
مصطلحات موضوعية: HETEROGENEITY, ADENOCARCINOMA, PROGRESSION-free survival, TUMORS, LUNG diseases
مستخلص: Treatment response and prognosis estimation in advanced pulmonary adenocarcinoma are challenged by the significant heterogeneity of the disease. The current Response Evaluation Criteria in Solid Tumors (RECIST) criteria, despite providing a basis for solid tumor response evaluation, do not fully encompass this heterogeneity. To better represent these nuances, we introduce the intertumoral heterogeneity response score (THRscore), a measure built upon and expanding the RECIST criteria. This retrospective study included patients with 3–10 measurable advanced lung adenocarcinoma lesions who underwent first‐line chemotherapy or targeted therapy. The THRscore, derived from the coefficient of variation in size for each measurable tumor before and 4–6 weeks posttreatment, unveiled a correlation with patient outcomes. Specifically, a high THRscore was associated with shorter progression‐free survival, lower tumor response rate, and a higher tumor mutation burden. These associations were further validated in an external cohort, confirming THRscore's effectiveness in stratifying patients based on progression risk and treatment response, and enhancing the utility of RECIST in capturing complex tumor behaviors in lung adenocarcinoma. These findings affirm the promise of THRscore as an enhanced tool for tumor response assessment in advanced lung adenocarcinoma, extending the RECIST criteria's utility. [ABSTRACT FROM AUTHOR]
Copyright of MedComm is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:26882663
DOI:10.1002/mco2.493